NASD · Healthcare · Diagnostics & Research · USA
GRAIL Inc is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
GRAIL Inc is a healthcare company that offers Galleri, a multi-cancer screening test detecting many cancer types from a single blood draw and predicting the tissue origin of detected signals. The company processes tests for healthcare systems, employers, payors, and life insurance providers. GRAIL has submitted its test for FDA approval.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the GRAIL Inc stock.
Overvalued: intrinsic value $21.40 per share, market price $105.88, margin of safety -394.7% (as of 2026-11-17).
A 1.6x revenue multiple, discounted for its losses, values the shares at $21.40; the price of $105.88 is 395% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
18 more in this industry show a wider margin of safety.
GRAL is overvalued (as of the 2026-11-17 close). A 1.6x revenue multiple, discounted for its losses, values the shares at $21.40; the price of $105.88 is 395% above that value.
$21.40 per share (as of the 2026-11-17 close), against a market price of $105.88. That is a margin of safety of -394.7%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.